After an extremely busy period of screening, negotiating and preparing applications for the Israeli Innovation authority (IIA), we are very happy to announce that 4 companies have been accepted into the eHV incubator (THE digital health incubator) and have officially started operations:
Food Allergies are a major health hazard in the western world, growing more and more widespread every year. In the USA, food allergies cause over 200,000 emergency room visits, 29,000 out which are due to anaphylactic shock. Some 100-200 of these anaphylaxis cases end in death. AllerGuard brings a new concept – a personal Allergen sensor. One that will enable the allergic person to scan their own food before consuming it, and know themselves whether or not it is safe for them. This hand-held device will scan and analyze the food compounds without taking samples from solid or liquid phase, and based on the chemical and physical properties of some very specific key elements, it will indicate if the Allergen is present in the dish.
100% of the population will develop skin abnormality during their lifetime, 31% will have a significant skin disease deserving a medical attention, and more than 50% won‘t receive an accurate diagnosis / fast treatment.
· In the UK – it takes more than half a year to get an appointment with a dermatology professional, in third world countries it might take years
· The Dermatology technologies market is expected to reach $20.4 Billion in 2020
· The Dermatology telemedicine segment is expected to reach $12 Billion in 4 years
The company is developing a non-intrusive solution for professional healthcare applications, as well as consumer & non-medical professionals to self-diagnose & treat skin disorders. The goal is to establish a direct connection between patient, professional, HMO & Pharma. Using an app to automatically detect skin problems can become an industry standard, and will in many cases dramatically increase chances to survive, as well as improve well-being by offering a treatment and/or connecting to the closest physician.
According to the International Osteoporosis Foundation (IOF), 1 in 3 women and 1 in 5 men are at risk of an osteoporotic fracture. Approximately 9 million osteoporotic fractures occur annually worldwide. According to the World Health Organization (WHO), Osteoporosis is second only to cardiovascular disease as a global healthcare problem and medical studies show a 50-year-old woman has a similar lifetime risk of dying from hip fracture as from breast cancer.
Over 70% of people at risk of Osteoporosis have never been diagnosed or screened. Primary care physicians, where most people get care, are rarely part of the diagnosis and treatment process.
Using OsteoSee’s unique parametric Electrical Impedance Tomography (pEIT), (i) a tabletop system will address the enormous unmet need of screening and diagnosing osteoporosis at the point-of-care, including at primary care physicians’ clinics; and (ii) for the first time, a wristband system connected to a smartphone will enable monitoring of osteoporosis patients undergoing treatment anywhere, including the home.
Today, ADHD diagnosis is completely subjective and is based on questionnaires. It leads to 20% of misdiagnosis which leads to prescription of the wrong medication.
Mind’sEye mobile platform is an objective diagnosis system based on eye biomarkers. The system identifies eye patterns that are unique to ADHD and provides the doctor with MEAS – Mind’sEye Attention Score according to which he can diagnose ADHD
The mobile system enables patients, for the first time, to monitor their ADHD throughout the day, see how medication or other activities affect their attention level and act accordingly.
Needless to say, we are proud of all 4 companies and their teams and wish the best of success to all.